Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Research Report 2023

Publication ID:

PB502233344

Publication Date:

February 17, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Chronic Graft-versus-host Disease (cGVHD) Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Chronic Graft-versus-host Disease (cGVHD) Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Chronic Graft-versus-host Disease (cGVHD) Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Chronic Graft-versus-host Disease (cGVHD) Treatment in Hospitals Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Chronic Graft-versus-host Disease (cGVHD) Treatment include Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company and Abbott Laboratories, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Graft-versus-host Disease (cGVHD) Treatment.
The Chronic Graft-versus-host Disease (cGVHD) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chronic Graft-versus-host Disease (cGVHD) Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Graft-versus-host Disease (cGVHD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Merck KGaA
Sanofi SA
Novartis AG
Bristol Myers Squibb
Pfizer
Roche Holding AG
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories
Takeda Pharmaceutical Company
Segment by Type
Corticosteroids
mTOR Inhibitors
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Graft-versus-host Disease (cGVHD) Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Corticosteroids
1.2.3 mTOR Inhibitors
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Monoclonal Antibodies
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Perspective (2018-2029)
2.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Growth Trends by Region
2.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Dynamics
2.3.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends
2.3.2 Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Drivers
2.3.3 Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Challenges
2.3.4 Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue
3.1.1 Global Top Chronic Graft-versus-host Disease (cGVHD) Treatment Players by Revenue (2018-2023)
3.1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue
3.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2022
3.5 Chronic Graft-versus-host Disease (cGVHD) Treatment Key Players Head office and Area Served
3.6 Key Players Chronic Graft-versus-host Disease (cGVHD) Treatment Product Solution and Service
3.7 Date of Enter into Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Type
4.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted 麻豆原创 Size by Type (2024-2029)
5 Chronic Graft-versus-host Disease (cGVHD) Treatment Breakdown Data by Application
5.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size (2018-2029)
6.2 North America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2018-2023)
6.4 North America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size (2018-2029)
7.2 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2018-2023)
7.4 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size (2018-2029)
9.2 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck KGaA
11.1.1 Merck KGaA Company Detail
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.1.4 Merck KGaA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.1.5 Merck KGaA Recent Development
11.2 Sanofi SA
11.2.1 Sanofi SA Company Detail
11.2.2 Sanofi SA Business Overview
11.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.2.4 Sanofi SA Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.2.5 Sanofi SA Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.3.4 Novartis AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Detail
11.4.2 Bristol Myers Squibb Business Overview
11.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.4.4 Bristol Myers Squibb Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.4.5 Bristol Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.5.4 Pfizer Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Roche Holding AG
11.6.1 Roche Holding AG Company Detail
11.6.2 Roche Holding AG Business Overview
11.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.6.4 Roche Holding AG Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.6.5 Roche Holding AG Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.7.5 Johnson & Johnson Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.8.4 Eli Lilly and Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.8.5 Eli Lilly and Company Recent Development
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Detail
11.9.2 Abbott Laboratories Business Overview
11.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.9.4 Abbott Laboratories Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.9.5 Abbott Laboratories Recent Development
11.10 Takeda Pharmaceutical Company
11.10.1 Takeda Pharmaceutical Company Company Detail
11.10.2 Takeda Pharmaceutical Company Business Overview
11.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Introduction
11.10.4 Takeda Pharmaceutical Company Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment Business (2018-2023)
11.10.5 Takeda Pharmaceutical Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Merck KGaA
Sanofi SA
Novartis AG
Bristol Myers Squibb
Pfizer
Roche Holding AG
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories
Takeda Pharmaceutical Company

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.